Acellera Therapeutics has developed a platform technology for localized immunessupression to treat immune-mediated disease, which leads to fewer off-target adverse effects.
People with transplanted livers face high risk of cancer and infection due to off-target effects of chronic immunessupression. This is a clear need in a $1.5 Bn market. Our solution improves patient health and decreases follow-up costs. Our pipeline also contains applications for type I diabetes and Crohn's disease.